Zacks: Analysts Expect ProPhase Labs, Inc. (NASDAQ: PRPH) to Post Quarterly Sales of $22.92 Million
Wall Street analysts expect ProPhase Labs, Inc. (NASDAQ:PRPH – Get Rating) to post revenue of $22.92 million for the current fiscal quarter, according to Zacks. Two analysts have made earnings estimates for ProPhase Labs. The highest sales estimate is $30.00 million and the lowest is $15.84 million. The company is expected to release its next quarterly results on Wednesday, March 30.
According to Zacks, analysts expect ProPhase Labs to report annual revenue of $56.81 million for the current fiscal year, with estimates ranging from $49.72 million to $63.90 million. of dollars. For next year, analysts expect the company to post sales of $51.67 million, with estimates ranging from $50.40 million to $52.93 million. Zacks Investment Research sales calculations are an average average based on a survey of research analysts who provide coverage for ProPhase Labs.
A number of equity analysts have weighed in on PRPH shares recently. Zacks Investment Research upgraded ProPhase Labs from a “hold” rating to a “buy” rating and set a price target of $7.75 on the stock in a Tuesday, February 22 report. StockNews.com launched coverage on ProPhase Labs in a report on Thursday. They put a “sell” mark on the stock. Finally, HC Wainwright raised its price target on ProPhase Labs from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, January 14. One financial analyst has assigned the stock a sell rating, one has assigned a hold rating and two have assigned the stock a buy rating. According to MarketBeat, ProPhase Labs currently has a consensus rating of “Hold” and a consensus price target of $11.38.
A number of institutional investors and hedge funds have recently changed their holdings in the company. Marshall Wace LLP purchased a new stake in ProPhase Labs in the third quarter worth approximately $119,000. HighVista Strategies LLC purchased a new stake in shares of ProPhase Labs during the third quarter at a value of approximately $105,000. Geode Capital Management LLC increased its position in ProPhase Labs shares by 3.1% during the third quarter. Geode Capital Management LLC now owns 105,857 shares of the company worth $550,000 after purchasing an additional 3,152 shares in the last quarter. Perritt Capital Management Inc. increased its stake in ProPhase Labs by 5.9% during the third quarter. Perritt Capital Management Inc. now owns 188,400 shares of the company valued at $980,000 after buying an additional 10,500 shares last quarter. Finally, Avidian Wealth Solutions LLC increased its stake in ProPhase Labs by 91.4% during the third quarter. Avidian Wealth Solutions LLC now owns 105,202 shares of the company valued at $547,000 after purchasing an additional 50,239 shares last quarter. Institutional investors and hedge funds own 10.64% of the company’s shares.
The NASDAQ PRPH opened at $6.65 on Monday. The company’s 50-day simple moving average is $6.93 and its two-hundred-day simple moving average is $6.30. ProPhase Labs has a 52-week minimum of $4.41 and a 52-week maximum of $8.48. The company has a quick ratio of 3.56, a current ratio of 4.42 and a leverage ratio of 0.21.
The company also recently announced a dividend, which was paid on Thursday, March 10. Shareholders of record on Tuesday, March 1 received a dividend of $0.30. The ex-dividend date was Monday, February 28.
About ProPhase Laboratories (Get an assessment)
ProPhase Labs, Inc is a medical science and technology company. It is engaged in the research, development, manufacture, distribution, marketing and sale of consumer health products and over-the-counter dietary supplements. The Company operates through the following business segments: Diagnostic Services and Consumer Products.
Get a Free Copy of Zacks Research Report on ProPhase Labs (PRPH)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in ProPhase Labs right now?
Before you consider ProPhase Labs, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and ProPhase Labs wasn’t on the list.
Although ProPhase Labs currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here